Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis
Soheila Rezaei, Behzad Fatemi, Zahra Karimi Majd, et al.
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 5, pp. 499-511
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

COVID-19: Inflammatory Profile
Yuhang Wang, Stanley Perlman
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 65-80
Open Access | Times Cited: 71
Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial
Payam Tabarsi, Nassim Anjidani, Ramin Shahpari, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 2, pp. 215-220
Open Access | Times Cited: 37
Beneficial and harmful outcomes of tocilizumab in severe COVID‐19: A systematic review and meta‐analysis
Manuel Rubio‐Rivas, Carlos G. Forero, José María Mora‐Luján, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2021) Vol. 41, Iss. 11, pp. 884-906
Open Access | Times Cited: 35
Title: Understanding a Low Vitamin D State in the Context of COVID-19
James Bernard Walsh, D. McCartney, Éamon Laird, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 13
Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19
Jing Zhang, Chun Chen, Yi Yang, et al.
Medicine (2022) Vol. 101, Iss. 9, pp. e28967-e28967
Open Access | Times Cited: 12
Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis
Jerin Jose Cherian, Madhavi Eerike, Bhavani Shankara Bagepally, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 12
Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis
Valeria Conti, Graziamaria Corbi, Carmine Sellitto, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 7, pp. 628-628
Open Access | Times Cited: 16
Efficacy of tocilizumab in the treatment of COVID‐19: An umbrella review
Mohammad Mahdi Rezaei Tolzali, Maryam Noori, Pourya Shokri, et al.
Reviews in Medical Virology (2022) Vol. 32, Iss. 6
Open Access | Times Cited: 11
Lack of Difference in Tocilizumab Efficacy in the Treatment of Severe COVID-19 Caused by Different SARS-CoV-2 Variants
Oleksandr Oliynyk, Wojciech Barg, Yanina Oliynyk, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 7, pp. 1103-1103
Open Access | Times Cited: 10
Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study
Ohoud Aljuhani, Khalid Al Sulaiman, Adel Alshabasy, et al.
BMC Infectious Diseases (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 13
Mitigating target interference challenges in bridging immunogenicity assay to detect anti-tocilizumab antibodies
Kamala Bhavaraju, Mamta Kumari Dhiman, H Desai, et al.
Bioanalysis (2024) Vol. 16, Iss. 12, pp. 587-602
Open Access | Times Cited: 1
Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
Alexia Plocque, Christie Mitri, Charlène Lefèvre, et al.
Drugs (2022) Vol. 83, Iss. 1, pp. 1-36
Open Access | Times Cited: 8
The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial
Farzaneh Dastan, Hamidreza Jamaati, Saghar Barati, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
Efficacy of intravenous immunoglobulins (IVIG) in COVID-19 patients: a systematic review and meta-analysis
Behzad Fatemi, Soheila Rezaei, Mohammad Peikanpour, et al.
Research in Pharmaceutical Sciences (2023) Vol. 18, Iss. 4, pp. 346-357
Open Access | Times Cited: 3
Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): A two-center, retrospective cohort study
Khalid Al Sulaiman, Ohoud Aljuhani, Khalid Bin Salah, et al.
Journal of Critical Care (2021) Vol. 66, pp. 44-51
Open Access | Times Cited: 7
Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study
Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, et al.
Journal of Intensive Care Medicine (2023) Vol. 38, Iss. 6, pp. 534-543
Open Access | Times Cited: 2
Determination of the Monoclonal Antibody Tocilizumab by a Validated Micellar Electrokinetic Chromatography Method
Sahar Zayed, Fathalla Belal
Chromatographia (2022) Vol. 85, Iss. 5, pp. 481-488
Open Access | Times Cited: 3
COMPARATIVE SAFETY EFFICACY OF CONVENTIONAL AND TRADITIONAL MEDICINE FOR COVID-19 TREATMENT: UMBRELLA REVIEW
Bukhari Bukhari, Sartika Maulida Putri, Asnawi Abdullah, et al.
International Journal of Medical Science and Public Health Research (2024) Vol. 05, Iss. 06, pp. 8-26
Open Access
Decoding NAD+ Metabolism in COVID-19: Implications for Immune Modulation and Therapy
Shixu Song, Jianhong Gan, Qiuyue Long, et al.
Vaccines (2024) Vol. 13, Iss. 1, pp. 1-1
Open Access
Unravelling the potentialities of tocilizumab for the development of a potential immunotherapeutic regimen against COVID-19—A narrative review
Manish Dhawan, Kuldeep Dhama, Manisha Parmar, et al.
Journal of Applied Pharmaceutical Science (2021)
Open Access | Times Cited: 4
The outcome of patients with Severe COVID 19 treated with tocilizumab:a Retrospective Cohort study
Jamil Muqtadir Bhatti, Syed Ali Raza, Noshirwan P. Gazder, et al.
(2023)
Open Access | Times Cited: 1
Inhibiteurs du récepteur de l’IL-6 dans le traitement de la COVID-19 : que savons-nous ?
Claude Lefèvre, Alexia Plocque, Michelle Tran, et al.
Revue des Maladies Respiratoires (2022) Vol. 40, Iss. 1, pp. 24-37
Open Access | Times Cited: 2
Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment
Gabriele Melegari, Enrico Giuliani, Chiara Dallai, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 11, pp. 1234-1234
Open Access | Times Cited: 2
Single Versus Multiple Doses of Tocilizumab in Critically Ill Patients with Coronavirus Disease 2019 (COVID-19): A Two-center, Retrospective Cohort Study
Khalid Al Sulaiman, Ohoud Al Juhani, Khalid Bin Salah, et al.
Research Square (Research Square) (2021)
Open Access | Times Cited: 2
Safety of Therapy with Tocilizumab and Other Interleukin Inhibitors
В. И. Петров, A. Yu. Ryazanova, D. A. Nekrasov, et al.
Safety and Risk of Pharmacotherapy (2022) Vol. 10, Iss. 1, pp. 34-47
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top